中国卫生标准管理
中國衛生標準管理
중국위생표준관리
CHINA HEALTH STANDARD MANAGEMENT
2014年
23期
168-170
,共3页
房颤%厄贝沙坦%疗效
房顫%阨貝沙坦%療效
방전%액패사탄%료효
Atrial fibril ation%Irbesartan%Curative effect
目的:探讨厄贝沙坦治疗房颤的临床疗效。方法选取我院在2011年1月至2014年1月收治的房颤患者60例,随机分为观察组和对照组,两组均给予胺碘酮治疗,观察组加用厄贝沙坦治疗,并比较两组左心房内径变化和窦性心律维持情况。结果观察组治疗后左心房内径为(36.5±3.7)mm,明显小于对照组(P<0.05);治疗12个月时共22例患者维持窦性心律,明显大于对照组(P<0.05)。结论厄贝沙坦在房颤治疗中作用效果显著,可明显改善患者左心房内径,维持正常心律。
目的:探討阨貝沙坦治療房顫的臨床療效。方法選取我院在2011年1月至2014年1月收治的房顫患者60例,隨機分為觀察組和對照組,兩組均給予胺碘酮治療,觀察組加用阨貝沙坦治療,併比較兩組左心房內徑變化和竇性心律維持情況。結果觀察組治療後左心房內徑為(36.5±3.7)mm,明顯小于對照組(P<0.05);治療12箇月時共22例患者維持竇性心律,明顯大于對照組(P<0.05)。結論阨貝沙坦在房顫治療中作用效果顯著,可明顯改善患者左心房內徑,維持正常心律。
목적:탐토액패사탄치료방전적림상료효。방법선취아원재2011년1월지2014년1월수치적방전환자60례,수궤분위관찰조화대조조,량조균급여알전동치료,관찰조가용액패사탄치료,병비교량조좌심방내경변화화두성심률유지정황。결과관찰조치료후좌심방내경위(36.5±3.7)mm,명현소우대조조(P<0.05);치료12개월시공22례환자유지두성심률,명현대우대조조(P<0.05)。결론액패사탄재방전치료중작용효과현저,가명현개선환자좌심방내경,유지정상심률。
Objective To investigate the clinical effect of irbesartan in the treatment of atrial fibrillation. Methods In our hospital in 2011 January to 2014 January 60 cases were patients with atrial fibrillation, were randomly dividedinto observation group and control group, two groups were treated withamiodarone treatment, the observation group were treated with irbesartan, and compared between the two groups of the change of left atrial diameterand sinus rhythm maintenance. Results The observation group after treatment,left atrial diameter was(36.5±3.7)mm,significantly less than the control group(P<0.05);treatment for 12 months, a total of 22 patients with sinus rhythm maintenance, significantly higher than the control group (P<0.05). Conclusion The effect of irbesartan in the treatment of AF effect significantly,can significantly improve the internal diameter of left atrium in patients withnormal heart rhythm.